Stabilitech Biopharma Ltd has developed a novel proprietary technology platform which protects vaccines and other biological products against production losses, including lyophilisation losses, and provides thermal stability over a range of temperatures including temperature fluctuations. It has been applied successfully to a variety of vaccine and protein classes, including adjuvanted vaccines. Stabilitech has now developed an oral delivery platform for vectors to enable the next generation of therapeutics to be generated in the gastrointestinal system.
Looking for a particular Stabilitech employee's phone or email?
The Stabilitech annual revenue was $11 million in 2026.
2 people are employed at Stabilitech.
Stabilitech is based in Burgess Hill, West Sussex.
The NAICS codes for Stabilitech are [32541, 325414, 3254, 325, 32].
The SIC codes for Stabilitech are [283, 28].